designer491
Coya Therapeutics (NASDAQ:COYA) shares reached a 52-week high on Tuesday after the company announced peer-reviewed data to support a new combination therapy for the neurodegenerative disorder amyotrophic lateral sclerosis (ALS).
The treatment regimen containing subcutaneous injections of commercial low-dose interleukin-2 (LD IL-2) and CTLA4-Ig fusion protein (CTLA4-Ig) is similar to the strategy Coya (COYA) intends to use against ALS with its lead asset, COYA 301.
The data published in the medical journal Frontiers in Neurology suggest that before starting the therapy, ALS patients were declining at an average rate of -1.1 points per month, according to the revised ALS Function Rating Scale (ALSFRS-R), a tool to monitor disease progression.
After six months of treatment, their ALSFRS-R scores changed at +0.04 points on average per month.
“In this open-label study, the efficacy as measured by the ALSFRS-R and corresponding biomarkers suggests the therapeutic potential of this treatment and warrants further study in a phase 2 double-blind, placebo-controlled trial,” researchers wrote in the article.
Coya (COYA) CEO Howard Berman said the company remains on track to seek FDA clearance to start a trial for its LD IL-2 + CTLA4-Ig combo for ALS this month.
